Method for transduction of t cells in the presence of malignant cells
AssigneeMiltenyi Biotec GmbH
InventorsNicole Cordes, Thomas Schaser, Andrew Kaiser
Life of this patent
Estimating the term…
Loading patent…
AssigneeMiltenyi Biotec GmbH
InventorsNicole Cordes, Thomas Schaser, Andrew Kaiser
Estimating the term…
The present invention provides an in-vitro method of reducing the efficiency of transducing malignant cells of the blood system of a subject that are not derived from T cells with lentiviral vector particles without reducing the efficiency of transducing T cells in a sample comprising T cells and said malignant cells. A combination of compositions comprising a first composition and a second composition is also disclosed, wherein said first composition comprises i) transduced T cells of a subject, wherein said transduced T cells express a CAR comprising an antigen binding domain, wherein the antigen binding domain of said CAR binds specifically to a tag of a tagged polypeptide, and ii) non-transduced malignant cells of the blood system of said subject, and wherein said second composition comprises said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of said malignant cells. Alternatively, the transduced T cells of said first composition may comprise a nucleic acid encoding a CAR and an inducible gene expression system, and said second composition may comprise an induction agent inducing said gene system.
An improved method for preparing a therapeutic population of T cells to treat a subject who has circulating malignant cells,
Dependencies are inferred from the claim text.